Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
16
2023-05
Boan Biotech’s BA1202 Approved for Clinical Trial The First Novel CEA/CD3 Bispecific Antibody in China
16
2023-05
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China
16
2023-05
Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302
11
2023-05
Boan Biotech Will Presents Results of Phase 3 Clinical Study for Denosumab Injection (BA1102) Conducted in China at the 2023 ASCO Annual Meeting
05
2023-05
First Subject Enrolled in Boan Biotech’s International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102
09
2023-05
Boan Biotech Releases Its First ESG Report, Shouldering ESG Responsibilities and Pursuing High-quality Development
13
2023-04
Boan to Remove “B” Marker from Its Stock Short Name at HKEX
11
2023-04
BLA for Boan's Boyounuo® (Bevacizumab) Accepted in Brazil
28
2023-03
Boan Biotech Announces 2022 Financial Results
21
2023-03
BLA Accepted in China for Boan Biotech’s Denosumab Injection (BA1102) for the Oncology Indications
2
3
4
5
6
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
